These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2535054)

  • 1. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.
    Leppert J; Jonasson T; Nilsson H; Ringqvist I
    Cardiovasc Drugs Ther; 1989 Jun; 3(3):397-401. PubMed ID: 2535054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitation of finger systolic pressure measurement as a diagnostic test for primary Raynaud's phenomenon in a female population.
    Leppert J
    Clin Physiol; 1989 Oct; 9(5):457-65. PubMed ID: 2582732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension.
    Kirch W; Burger KJ; Weidinger G; Welzel D
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S55-9. PubMed ID: 1695304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol.
    Cantor A; Cristal N
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S76-8. PubMed ID: 1695309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.
    Bounameaux HM; Hellemans H; Verhaege R
    Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine.
    Welzel D; Burger KJ; Weidinger G
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S70-4. PubMed ID: 1695308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter comparison of isradipine and prazosin for treatment of essential hypertension.
    Swartz SL; Gonasun LM; McAllister RG; Thadani U
    Cardiovasc Drugs Ther; 1990 Apr; 4(2):413-7. PubMed ID: 2149512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud's phenomenon.
    La Civita L; Giuggioli D; Del Chicca MG; Longombardo G; Pasero G; Ferri C
    Ann Rheum Dis; 1996 May; 55(5):331-2. PubMed ID: 8660111
    [No Abstract]   [Full Text] [Related]  

  • 13. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist.
    Nelson EB; Pool JL; Taylor AA
    Clin Pharmacol Ther; 1986 Dec; 40(6):694-7. PubMed ID: 2946507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension.
    Sundstedt CD; Rüegg PC; Keller A; Waite R
    Am J Med; 1989 Apr; 86(4A):98-102. PubMed ID: 2523665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of isradipine (PN 200-110) in mild to moderate hypertension.
    Winer N; Thys-Jacobs S; Kumar R; Davidson WD; Grayson M; Harris C; Walker D; Itskovitz H; Gonasun L
    Clin Pharmacol Ther; 1987 Oct; 42(4):442-8. PubMed ID: 2959426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved blood pressure control with isradipine in hypertensive patients treated with pindolol.
    Frithz G; Aström B; Dahlöf B; Hansson L; Tollin C; Himanen P; Sundstedt CD
    Am J Med; 1989 Apr; 86(4A):115-8. PubMed ID: 2523645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term effect of isradipine in pindolol-treated patients.
    Dahlöf B; Andrén L; Eggertsen R; Jern S; Svensson A; Hansson L
    J Hypertens Suppl; 1987 Dec; 5(5):S567-70. PubMed ID: 2965231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon.
    Coffman JD; Rasmussen HM
    Circulation; 1985 Sep; 72(3):466-70. PubMed ID: 2861920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isradipine in essential hypertension: the Belgian General Practitioners' Study.
    De Keyser P; Bouvé J; Clement D; Degraef R; Meurant JP; Rorive G; Van Thillo J
    Am J Med; 1989 Apr; 86(4A):103-9. PubMed ID: 2565687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.